Product Description
A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal, Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: France | India | Slovenia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer|Deficiency Diseases|Inflammation|Pregnancy Outcomes|Pituitary Cancer|Testicular Diseases|Hypothalamic Cancer|Skin Diseases, Vascular|Prostatic Diseases|Hypothalamic Diseases|Bladder Cancer|Hypogonadism|Vascular Cancer|Protein Deficiency|Pituitary Diseases|Skin Cancer|Prostatic Hyperplasia|Testicular Cancer|Hypopituitarism|Bone Cancer|Breast Cancer
Phase 1: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01724619 |
IRB00015971 | P1 |
Terminated |
Prostate Cancer |
2013-03-01 |
2019-03-19 |
||
2014-005684-32 |
FDHT - version 1, 9 March 2015 | P2 |
Terminated |
Prostate Cancer |
2018-09-15 |
2022-03-13 |
Treatments |
|
2013-002415-10 |
[18F]FDHT PET in hormone naive prostate cancer | P2 |
Active, not recruiting |
Prostate Cancer|Bone Cancer |
2016-02-11 |
2022-03-13 |
Treatments |
|
2012-003981-42 |
2012-003981-42 | P2 |
Completed |
Breast Cancer |
2015-05-13 |
2025-07-09 |
Treatments |
|
NCT00490022 |
DHT-3 | P2 |
Completed |
Hypogonadism|Inflammation|Hypopituitarism|Hypothalamic Cancer|Pregnancy Outcomes|Pituitary Diseases|Skin Diseases, Vascular|Hypothalamic Diseases|Pituitary Cancer|Skin Cancer|Vascular Cancer|Testicular Diseases|Prostatic Hyperplasia|Bladder Cancer|Testicular Cancer|Protein Deficiency|Prostate Cancer|Prostatic Diseases|Deficiency Diseases |
2009-01-01 |
2019-03-21 |
Treatments |
|
NCT00163566 |
03-DHT-01 | P2 |
Completed |
Hypogonadism |
2006-09-01 |
2022-08-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |